AGN-242428 is under clinical development by AbbVie and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AGN-242428’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGN-242428 (VTP-43742) is under development for the treatment of keratoconjunctivitis sicca (Dry Eye). It is administered through oral and ophthalmic route. It targets RAR-Related orphan receptor gamma t (ROR gamma t). The drug candidate is developed based on proprietary Contour SBDD (structure-based drug design) platform. It is a new molecular entity.
It was under development for the treatment of presbyopia, autoimmune disorders, including plaque psoriasis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, inflammatory bowel disease and various rare and orphan disorders.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of AGN-242428’s drug-specific PTSR and LoA scores, buy the report here.